Cencora, Inc. (NYSE:COR) Shares Acquired by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Cencora, Inc. (NYSE:COR) by 3.1% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 90,767 shares of the company’s stock after acquiring an additional 2,711 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Cencora were worth $20,430,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the stock. Pacer Advisors Inc. lifted its stake in Cencora by 6,855.3% during the third quarter. Pacer Advisors Inc. now owns 2,065,374 shares of the company’s stock worth $464,874,000 after purchasing an additional 2,035,679 shares in the last quarter. Legal & General Group Plc raised its holdings in shares of Cencora by 3.7% in the 2nd quarter. Legal & General Group Plc now owns 1,875,445 shares of the company’s stock valued at $422,538,000 after buying an additional 67,287 shares during the period. Swedbank AB lifted its stake in Cencora by 2.3% during the 3rd quarter. Swedbank AB now owns 1,394,449 shares of the company’s stock worth $313,863,000 after acquiring an additional 31,104 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in Cencora by 10.5% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,262,882 shares of the company’s stock valued at $284,544,000 after acquiring an additional 119,927 shares during the period. Finally, Bank of New York Mellon Corp grew its position in Cencora by 0.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,205,673 shares of the company’s stock valued at $271,638,000 after acquiring an additional 4,697 shares in the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Trading Up 0.8 %

COR opened at $251.60 on Friday. The company has a debt-to-equity ratio of 4.84, a quick ratio of 0.53 and a current ratio of 0.88. Cencora, Inc. has a one year low of $195.83 and a one year high of $253.27. The company has a market cap of $49.58 billion, a P/E ratio of 33.50, a PEG ratio of 1.66 and a beta of 0.44. The business’s 50-day simple moving average is $234.91 and its 200-day simple moving average is $232.46.

Cencora Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, November 29th. Shareholders of record on Friday, November 15th were issued a dividend of $0.55 per share. The ex-dividend date of this dividend was Friday, November 15th. This represents a $2.20 dividend on an annualized basis and a yield of 0.87%. This is a boost from Cencora’s previous quarterly dividend of $0.51. Cencora’s dividend payout ratio (DPR) is presently 29.29%.

Insider Transactions at Cencora

In related news, Chairman Steven H. Collis sold 21,509 shares of Cencora stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $242.16, for a total transaction of $5,208,619.44. Following the sale, the chairman now directly owns 306,752 shares in the company, valued at $74,283,064.32. This trade represents a 6.55 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In the last quarter, insiders sold 93,018 shares of company stock worth $22,478,942. 15.80% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on COR shares. UBS Group raised their price objective on shares of Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Barclays raised their price target on shares of Cencora from $263.00 to $290.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. Leerink Partners cut their price objective on Cencora from $277.00 to $275.00 and set an “outperform” rating on the stock in a research report on Monday, October 7th. Bank of America reiterated a “neutral” rating and issued a $245.00 target price (down from $275.00) on shares of Cencora in a report on Wednesday, September 18th. Finally, StockNews.com downgraded Cencora from a “strong-buy” rating to a “buy” rating in a report on Friday, September 20th. Three analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $271.20.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.